Physician profile
Case C Everett
NPI 1144481441
$725.41
in general payments reported to CMS, 2019-2025
15 companies · $34.28 in 2025
The $34.28 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.07 · 2020: $15.45 · 2023: $147 · 2024: $487 · 2025: $34.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $213.12 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $93.03 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.39 | 2023-2024 | Jardiance |
| Pfizer INC. | $62.43 | 2023-2024 | |
| Novo Nordisk INC | $55.80 | 2019-2024 | Wegovy |
| Merck Sharp & Dohme LLC | $52.02 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $45.85 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $20.52 | 2024 | |
| Phathom Pharmaceuticals, INC. | $18.90 | 2024 | Voquezna |
| Astellas Pharma US INC | $18.54 | 2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $18.04 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.19 | 2023 | Gvoke Hypopen |
| Medtronic, INC. | $15.79 | 2024 | Minimed 780g |
| Regeneron Healthcare Solutions, INC. | $14.30 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.49 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Case Everett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.